In the future, the leading cell therapy for blindness will not only stop retinal degeneration but will also reverse it.
Retinal pigmented epithelium (RPE) and photoreceptor cells (cones and rods) will both be replaced or regenerated. Alpine BioTherapeutics is committed to developing a therapy based on a progenitor or precursor to retinal cells. This cell will either differentiate into or enhance regeneration of RPEs and photoreceptors in vivo.
Our mission is to create a stem cell-based therapy to preserve and restore eye sight in patients afflicted by dry age-related macular degeneration (dry-AMD) and retinitis pigmentosa (RP). We have developed a proprietary technology to manufacture retinal progenitor-like multipotent stem cell products that are derived from human pluripotent stem cells. This retinal stem cell product will differentiate into, or enhance regeneration of, photoreceptor and RPE in vivo.
AMD is a visual disorder characterized by a large blind spot in the center of the field of vision. There are two types of AMD: Wet and Dry. In Dry-AMD, small white-yellow deposits called drusen form on the center of the retina which causes it to to degenerate over time. About 80% of all AMD cases are dry-AMD. Currently, there is no effective therapy for dry-AMD.
RP is a genetic disorder which affects 1 in 4000 people that leads to the loss of photoreceptors in the back of the eye. Late stage characteristics include severe tunnel vision and night blindness.